Agreements (Details 7) (USD $)	3 Months Ended								12 Months Ended						31 Months Ended				1 Months Ended			12 Months Ended	31 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014 Lilly	Jun. 30, 2013 Lilly	Jun. 30, 2012 Lilly	Jun. 30, 2014 Lilly	Jun. 30, 2014 Lilly Sales milestones	Jun. 30, 2014 Lilly Future Technological Improvements	Jun. 30, 2014 Lilly Research Services	Dec. 31, 2011 Lilly Right-to-test agreement	Dec. 31, 2013 Lilly Development and Commercialization License	Dec. 31, 2011 Lilly Development and Commercialization License item	Jun. 30, 2014 Lilly Development and Commercialization License	Jun. 30, 2014 Lilly Development and Commercialization License	Dec. 31, 2011 Lilly Development and Commercialization License No exercise fee	Dec. 31, 2011 Lilly Development and Commercialization License No exercise fee Maximum	Dec. 31, 2011 Lilly Development and Commercialization License Exercise fee of $2 million	Dec. 31, 2011 Lilly Development and Commercialization License Exercise fee of $2 million Maximum	Dec. 31, 2011 Lilly Development and Commercialization License Development milestones No exercise fee	Dec. 31, 2011 Lilly Development and Commercialization License Development milestones Exercise fee of $2 million	Jun. 30, 2014 Lilly Development and Commercialization License Development milestones Phase I clinical trial	Dec. 31, 2011 Lilly Development and Commercialization License Regulatory milestones	Dec. 31, 2011 Lilly Development and Commercialization License Sales milestones
Collaborative Agreements disclosures
Term of agreement																			3 years
Payments received under collaboration agreement															$ 28,200,000	$ 800,000	$ 600,000	$ 3,300,000	$ 20,000,000	$ 2,000,000			$ 23,500,000
Potential milestone payments for each subsequent license																						2,000,000	2,000,000		200,500,000		199,000,000	30,500,000	29,000,000	5,000,000	70,000,000	100,000,000
Number of development and commercialization licenses taken																					2
License exercise fee, per subsequent license																					2,000,000			0		2,000,000
Estimated utilization period after commercialization																						10 years
Discount rate (as a percent)																						16.00%
Amount of arrangement consideration included in license and milestone fees	305,000	305,000	25,678,000	13,167,000	855,000	22,010,000	429,000	933,000	39,455,000	24,227,000	9,161,000											7,800,000
Estimated term of development and commercialization license																						25 years
Remaining arrangement consideration to be recognized as license revenue																						15,700,000	15,700,000
Costs related to the research and development services	25,787,000	38,280,000	20,862,000	22,029,000	20,399,000	21,318,000	21,656,000	23,700,000	106,958,000	87,073,000	69,192,000	1,200,000	310,000	94,000
Costs related to clinical materials sold												$ 26,000	$ 10,000	$ 0